{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:14:10Z","timestamp":1762503250190,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T00:00:00Z","timestamp":1630972800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011676","name":"Elekta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011676","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002669","name":"Elekta AB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002669","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ctro.2021.09.002","type":"journal-article","created":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T13:49:49Z","timestamp":1635256189000},"page":"159-164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Outcomes and toxicities in oligometastatic patients treated with stereotactic body radiotherapy for adrenal gland metastases: A multi-institutional retrospective study"],"prefix":"10.1016","volume":"33","author":[{"given":"A.","family":"Baydoun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Poon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Badellino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Dagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Erler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.C.","family":"Foote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.V.","family":"Louie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.J.","family":"Redmond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Ricardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Sahgal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2021.09.002_b0005","unstructured":"Tipton KN, Sullivan N, Bruening W, Inamdar R, Launders J, Uhl S, et al. Stereotactic body radiation therapy. 2011."},{"issue":"1","key":"10.1016\/j.ctro.2021.09.002_b0010","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctro.2021.09.002_b0015","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrclinonc.2014.96","article-title":"The oligometastatic state\u2014separating truth from wishful thinking","volume":"11","author":"Palma","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctro.2021.09.002_b0020","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1200\/JCO.2008.19.6386","article-title":"Multi-institutional phase I\/II trial of stereotactic body radiation therapy for lung metastases","volume":"27","author":"Rusthoven","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctro.2021.09.002_b0025","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1080\/02841860600908954","article-title":"Stereotactic body radiation therapy (SBRT) for lung metastases","volume":"45","author":"Okunieff","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctro.2021.09.002_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13014-018-1185-9","article-title":"Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up","volume":"13","author":"Scorsetti","year":"2018","journal-title":"Radiation Oncology."},{"issue":"4","key":"10.1016\/j.ctro.2021.09.002_b0035","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1470-2045(11)70384-9","article-title":"Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1\u20132 trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ctro.2021.09.002_b0040","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1634\/theoncologist.2012-0092","article-title":"Review and uses of stereotactic body radiation therapy for oligometastases","volume":"17","author":"Alongi","year":"2012","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.ctro.2021.09.002_b0045","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1002\/cncr.26611","article-title":"Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease","volume":"118","author":"Salama","year":"2012","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ctro.2021.09.002_b0050","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/acm2.12308","article-title":"Comparative analysis for renal stereotactic body radiotherapy using Cyberknife, VMAT and proton therapy based treatment planning","volume":"19","author":"Baydoun","year":"2018","journal-title":"Journal of applied clinical medical physics."},{"key":"10.1016\/j.ctro.2021.09.002_b0055","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/B978-1-4377-2232-1.00031-0","article-title":"Metastases to abdominal-pelvic organs","author":"Faria","year":"2012","journal-title":"Oncologic Imaging: A Multidisciplinary Approach: Elsevier Health Sciences"},{"key":"10.1016\/j.ctro.2021.09.002_b0060","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1046\/j.0300-0664.2001.01435.x","article-title":"Metastatic tumours of the adrenal glands: a 30-year experience in a teaching hospital","volume":"56","author":"Lam","year":"2002","journal-title":"Clin Endocrinol"},{"issue":"2","key":"10.1016\/j.ctro.2021.09.002_b0065","first-page":"279","article-title":"Practical approach to adrenal imaging","volume":"55","author":"Elsayes","year":"2017","journal-title":"Radiologic Clinics."},{"issue":"4","key":"10.1016\/j.ctro.2021.09.002_b0070","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s13304-015-0336-x","article-title":"Oligometastatic non-small cell lung cancer (NSCLC): adrenal metastases. Experience in a single institution","volume":"67","author":"Barone","year":"2015","journal-title":"Updates in surgery."},{"key":"10.1016\/j.ctro.2021.09.002_b0075","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00732","article-title":"Usefulness of Stereotactic Body Radiation Therapy for Treatment of Adrenal Gland Metastases","volume":"9","author":"Scouarnec","year":"2019","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.ctro.2021.09.002_b0080","first-page":"179","article-title":"Sitges-Serra AJLsaos","volume":"397","author":"Sancho","year":"2012","journal-title":"Surgical Management Adrenal Metastases."},{"key":"10.1016\/j.ctro.2021.09.002_b0085","doi-asserted-by":"crossref","unstructured":"Tamura T, Kurishima K, Nakazawa K, Kagohashi K, Ishikawa H, Satoh H, et al. Specific organ metastases and survival in metastatic non\u2011small\u2011cell lung cancer. 2015;3:217-21.","DOI":"10.3892\/mco.2014.410"},{"issue":"1","key":"10.1016\/j.ctro.2021.09.002_b0090","first-page":"48","article-title":"Stereotactic Body Radiation Therapy of Adrenal Metastases: A Pooled Meta-Analysis and Systematic Review of 39 Studies with 1006 Patients. International Journal of Radiation Oncology* Biology*","volume":"107","author":"Chen","year":"2020","journal-title":"Physics."},{"key":"10.1016\/j.ctro.2021.09.002_b0095","first-page":"1","article-title":"Clinical efficacy of Stereotactic Body Radiation Therapy (SBRT) for adrenal gland metastases: A multi-center retrospective study from China","volume":"10","author":"Zhao","year":"2020","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.ctro.2021.09.002_b0100","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/ijc.33546","article-title":"Stereotactic or conformal radiotherapy for adrenal metastases: Patient characteristics and outcomes in a multicenter analysis","volume":"149","author":"Buergy","year":"2021","journal-title":"Int J Cancer"},{"issue":"11","key":"10.1016\/j.ctro.2021.09.002_b0105","doi-asserted-by":"crossref","first-page":"e2026312","DOI":"10.1001\/jamanetworkopen.2020.26312","article-title":"Evaluation of Definitive Stereotactic Body Radiotherapy and Outcomes in Adults With Extracranial Oligometastasis","volume":"3","author":"Poon","year":"2020","journal-title":"JAMA network open."},{"issue":"1","key":"10.1016\/j.ctro.2021.09.002_b0110","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ctro.2021.09.002_b0115","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.2217\/fon-2016-0479","article-title":"A multinational report of technical factors on stereotactic body radiotherapy for oligometastases","volume":"13","author":"Redmond","year":"2017","journal-title":"Future Oncol"},{"key":"10.1016\/j.ctro.2021.09.002_b0120","first-page":"141","article-title":"An empirical transition matrix for non-homogeneous Markov chains based on censored observations","author":"Aalen","year":"1978","journal-title":"Scand J Stat"},{"issue":"282","key":"10.1016\/j.ctro.2021.09.002_b0125","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"446","key":"10.1016\/j.ctro.2021.09.002_b0130","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ctro.2021.09.002_b0135","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J Roy Stat Soc: Ser B (Methodol)"},{"key":"10.1016\/j.ctro.2021.09.002_b0140","unstructured":"Team RC. R: A language and environment for statistical com\u2010puting. Vienna, Austria: R Foundation for Statistical Computing. Retrieved from\u2026; 2017."},{"key":"10.1016\/j.ctro.2021.09.002_b0145","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: a cancer journal for clinicians. 2020;70:7-30.","DOI":"10.3322\/caac.21590"},{"issue":"4","key":"10.1016\/j.ctro.2021.09.002_b0150","doi-asserted-by":"crossref","first-page":"e0195149","DOI":"10.1371\/journal.pone.0195149","article-title":"Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: a multi-institutional pooled analysis","volume":"13","author":"Hong","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctro.2021.09.002_b0155","doi-asserted-by":"crossref","first-page":"20130681","DOI":"10.1259\/bjr.20130681","article-title":"Survey of stereotactic ablative body radiotherapy in the UK by the QA group on behalf of the UK SABR Consortium","volume":"87","author":"Distefano","year":"2014","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ctro.2021.09.002_b0160","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1177\/0300891620929425","article-title":"Dose prescription in SBRT for early-stage non-small cell lung cancer: are we all speaking the same language?","volume":"107","author":"Merlotti","year":"2021","journal-title":"Tumori J"},{"key":"10.1016\/j.ctro.2021.09.002_b0165","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2019.11.001","article-title":"Variation in current prescription practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer: recommendations for prescribing and recording according to the ACROP guideline and ICRU report 91","volume":"142","author":"de Jong","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2021.09.002_b0170","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00066-018-1416-x","article-title":"ICRU report 91 on prescribing, recording, and reporting of stereotactic treatments with small photon beams","volume":"195","author":"Wilke","year":"2019","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ctro.2021.09.002_b0175","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.adro.2018.05.006","article-title":"Stereotactic body radiation therapy for adrenal gland metastases: Outcomes and toxicity","volume":"3","author":"Toesca","year":"2018","journal-title":"Adv Rad Oncol"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240563082100080X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240563082100080X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:09:50Z","timestamp":1762502990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240563082100080X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":35,"alternative-id":["S240563082100080X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2021.09.002","relation":{},"ISSN":["2405-6308"],"issn-type":[{"type":"print","value":"2405-6308"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes and toxicities in oligometastatic patients treated with stereotactic body radiotherapy for adrenal gland metastases: A multi-institutional retrospective study","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2021.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}]}}